NPR's Steve Inskeep asks Youseph Yazdi, a professor at Johns Hopkins School of Medicine, about his recent visit to Iran, where thousands have been killed in anti-government protests. Youseph Yazdi is ...

CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...

Prof. Booth is Professor of Engineering Science at the University of Oxford. His research involves the development and application of adaptive optical methods in microscopy, laser-based materials ...

FLATIRON DISTRICT, Manhattan (WABC) -- As a college math professor, Steve Warner knows a thing or two about crunching numbers. After he purchased his apartment in 2022, however, Warner met a problem ...

Valentine's Day is shaping up to be a beautiful, mild day with highs climbing into the low 50s.We will see temperatures rise into the mid-50s for Sunday with in Mother of man killed by carbon monoxide ...

After over a month of government shutdown, NASA finally released new images of mysterious interstellar object 3I/ATLAS on Wednesday. During the livestreamed event, NASA brass took pains to “address ...

The recent release of thousands of emails that late sex offender Jeffrey Epstein exchanged with associates has renewed interest in the disgraced financier’s connection to star Harvard University ...

Harvard Psychology professor Steven A. Pinker condemned the rise of cancel culture in higher education at an Institute of Politics forum on Wednesday, telling his audience that academics must avoid ...

Harvard psychology professor Steven Pinker said there was a "grain of truth" to President Donald Trump's argument that Harvard University was a "liberal mess." "President Trump has described Harvard ...

For generations, federal research funding to universities has fueled breakthroughs in medicine, technology, and national defense. Now, the White House is using that support as leverage — pressuring a ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...